NCT04542967View on ClinicalTrials.gov

Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

September 2, 2020

Study Completion Date

September 30, 2020

Conditions
Severe COVID-19 Disease
Interventions
BIOLOGICAL

Biological

"An administration unit of 200 ml convalescent plasma intravenous infusion every 24 hours for two doses.~If a third dose of convalescent plasma is necessary, it may be used, as long as an evaluation of the research team is carried out."

Trial Locations (1)

11200

Hospital Central Militar, Mexico City

All Listed Sponsors
lead

Hospital Central Militar

OTHER_GOV

NCT04542967 - Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease | Biotech Hunter | Biotech Hunter